DOCSLIB.ORG

OSTEOPOROSIS New Data Enhance Our Understanding of the Effects of Some Contraceptives and Key Serms on the Skeletal Health of Users

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
OSTEOPOROSIS New Data Enhance Our Understanding of the Effects of Some Contraceptives and Key Serms on the Skeletal Health of Users UPDATE OSTEOPOROSIS New data enhance our understanding of the effects of some contraceptives and key SERMs on the skeletal health of users ›› Steven R. Goldstein, MD Dr. Goldstein is Professor of Obstetrics and Gynecology at New York University School of Medicine and Director of Gynecologic Ultrasound and Co-Director of Bone Densitometry at NYU Medical Center in New York City. He serves on the OBG Management Board of Editors. Th e author reports that he serves on the advisory boards of Amgen, Boehringer Ingelheim, Depomed, Eli Lilly, and Novo Nordisk. He is a speaker for the Alliance for Bone Health, Eli Lilly, and Warner Chilcott. Some hormonal contraceptives may aff ect bone® Dowdendensity Health Media Berenson AB, Rahman M, Breitkopf CR, Bi LX. Eff ects of colleagues reported a 7.8% increase in BMD depot medroxyprogesterone acetateCopyright and 20-microgramFor personalover 5 years amonguse womenonly 19 to 22 years oral contraceptives on bone mineral density. Obstet old who did not use OCs, compared with no IN THIS Gynecol. 2008;112:788–799. ARTICLE change in BMD among women who used OCs American College of Obstetricians and Gynecologists. containing 20 μg of ethinyl estradiol.2 How does denosumab ACOG Committee Opinion. No. 415. September 2008. compare with Depot medroxyprogesterone acetate and bone eff ects. DMPA, BMD, and the FDA Obstet Gynecol. 2008;112:727–730. alendronate? Th e deleterious eff ect of DMPA on BMD page 26 is particularly relevant in perimenopausal woman’s contraceptive choice may women, who have already begun to experi- A aff ect her bone mineral density ence the age-related decline in BMD that Another SERM (BMD)—particularly if she chooses depot starts around the age of 30. Th e eff ect is also bites the dust medroxyprogesterone acetate (DMPA) or troubling in adolescents, who normally ex- page 27 a very-low-dose oral contraceptive (OC) as perience a large accretion of bone during her method. the teen and early adult years. TSEC, a novel In the case of DMPA, studies have shown In 2004, the US Food and Drug Admin- compound, enters that its use for 2 years signifi cantly impairs istration (FDA) added a boxed warning to development BMD at the hip and spine, regardless of the DMPA labeling advising women to limit their patient’s age, although BMD usually re- use of the drug to 2 years. Since that time, page 27 bounds after discontinuation of the drug.1 other studies have found that BMD increas- In the case of very-low-dose OCs, there es to a greater degree among past users of is evidence that young women who use a pill DMPA than among never users—suggesting that contains only 20 μg of ethinyl estradiol that DMPA-related bone loss is reversible. have a lower increase in BMD than do women the same age who do not use hormonal con- ACOG: DMPA can be used traception. (OCs that contain a higher dos- longer than 2 years in some age of ethinyl estradiol have not been shown In September 2008, the American College to hamper BMD.) A study by Polatti and of Obstetricians and Gynecologists (ACOG) obgmanagement.com Vol. 21 No. 11 | November 2009 | OBG Management 21 For mass reproduction, content licensing and permissions contact Dowden Health Media. 21_r1_OBGM1109 21 10/23/09 3:46:23 PM UPDATE osteoporosis FIGURE DMPA-related bone loss is largely reversible Hip Spine Normal Loss of bone density Depot medroxyprogesterone acetate (DMPA) is associated with a loss of bone mineral density at the hip and spine. Once the drug is discontinued, however, bone density appears to recover at least partially at both sites. ROB FLEWELL FOR OBG MANAGEMENT released a committee opinion acknowledg- loss. Th e committee pointed out, however, ing the association between DMPA and BMD that “current evidence suggests that partial or full recovery of BMD occurs at the spine ACOG: Given the and at least partial recovery occurs at the hip effi cacy of DMPA, WHAT THIS EVIDENCE MEANS after discontinuation of DMPA” (FIGURE). the drug may be a FOR PRACTICE Th e ACOG opinion also noted that, good option in some “given the effi cacy of DMPA, particularly for Use of very-low-dose oral contraception populations, populations such as adolescents, for whom (20 μg ethinyl estradiol) may lead to contraceptive adherence can be challenging, despite its effects a small amount of bone loss or failure or for those who feel they could not com- on bone density of bone accretion. Use of depot ply with a daily contraceptive method or a medroxyprogesterone acetate (DMPA) method that must be used with each act of is associated with a greater degree of intercourse, the possible adverse eff ects of bone loss, but this loss is largely reversible at the spine. Use of a 20-μg DMPA must be balanced against the signifi - oral contraceptive (OC) after discon- cant personal and public health impact of tinuation of DMPA may slow bone unintended pregnancy.” recovery. Th e committee recommended that, de- As ACOG has indicated, concerns spite concerns about bone loss, practitioners about skeletal health should not infl uence should not hesitate to prescribe DMPA. Nor the decision to initiate or continue DMPA. should they limit its use to 2 consecutive Likewise, such concerns should not lead years or perform BMD monitoring solely to restrictions on the use of OCs in teens in response to DMPA use. “Any observed or adult women. However, clinicians may short-term loss in BMD associated with wish to take bone effects into consider- DMPA use may be recovered and is unlikely ation when choosing the estrogen dos- age of OCs for women younger than 30 to place a woman at risk of fracture during who have yet to attain peak bone mass. use or in later years,” the committee opinion noted. CONTINUED ON PAGE 24 22 OBG Management | November 2009 | Vol. 21 No. 11 22_r1_OBGM1109 22 10/23/09 3:46:28 PM UPDATE osteoporosis Study explores bone gains after DMPA OCs (20 μg ethinyl estradiol), compared with Berenson and associates measured BMD a gain of 1.9% at the lumbar spine and 0.6% every 6 months for as long as 3 years in 703 at the femoral neck in nonusers of hormonal white, African-American, and Hispanic wom- contraception. en who used an OC, DMPA, or nonhormonal Women who made a transition from contraception. Th ey also measured BMD for DMPA to a very-low-dose OC recovered bone up to 2 additional years in 68 women who mass slowly. After DMPA was discontinued, discontinued DMPA. Th ey found no diff er- women who selected nonhormonal contra- ences between races—although they did fi nd ception recovered BMD (4.9% at the spine, the expected DMPA-associated bone loss. 3.2% at the femoral neck)—unlike those who Th ey also found a small amount of bone chose a very-low-dose OC, who regained loss (0.5% at the lumbar spine and 1.3% at BMD at the spine (2.3%) but not the femoral the femoral neck) in users of very-low-dose neck (–0.7%). Denosumab nears FDA approval for treatment of osteoporosis Cummings SR, San Martin J, McClung MR, et al; Trial: Denosumab versus placebo FREEDOM trial. Denosumab for prevention of Cummings and colleagues reported the fi nd- fractures in postmenopausal women with ings of the Fracture Reduction Evaluation of osteoporosis. N Engl J Med. 2009;361:756–765. Denosumab in Osteoporosis Every 6 Months Kendler DL, Roux C, Benhamou CL, et al. Eff ects of (FREEDOM) trial, which involved 7,868 New vertebral denosumab on bone mineral density and bone turn- women 60 to 90 years old who had a BMD over in postmenopausal women transitioning from T-score between –2.5 and –4.0 at the lumbar fractures occurred alendronate therapy. J Bone Miner Res. 2009 [Epub at a rate of 2.3% ahead of print]. spine or total hip. Participants were random- among women ly assigned to receive 60 mg of denosumab or Miller PD, Bolognese MA, Lewiecki EM, et al, for the taking denosumab, placebo subcutaneously every 6 months for Amg Bone Loss Study Group. Eff ect of denosumab on 36 months. Th e primary endpoint was new versus 7.2% among bone density and turnover in postmenopausal women vertebral fracture. Secondary endpoints in- those taking placebo with low bone mass after long-term continued, dis- continued, and restarting of therapy: a randomized cluded nonvertebral and hip fractures. blinded phase 2 clinical trial. Bone. 2008;43:222–229. Findings included: • Denosumab reduced the risk of new, n FDA panel advising the Division of radiographically detected vertebral AReproductive and Urologic Products fracture, with a cumulative incidence of voted to approve denosumab (proposed 2.3%, versus 7.2% in the placebo group brand name: Prolia) as a treatment for os- (risk ratio, 0.32; P<.001). teoporosis. Th e drug is a fully human mono- • Denosumab reduced the risk of hip clonal antibody to the receptor activator of fracture, with a cumulative incidence nuclear factor-B ligand (RANKL), a cytokine of 0.7% in the denosumab group, versus that is essential for the formation, func- 1.2% in the placebo group (hazard ratio, tion, and survival of osteoclasts. By binding 0.60; P=.04). RANKL, denosumab prevents interaction • Denosumab reduced the risk of nonver- between RANKL and its receptor, RANK, on tebral fracture, with a cumulative inci- osteoclasts and osteoclast precursors and dence of 6.5% in the denosumab group, thereby inhibits osteoclast-mediated bone versus 8.0% in the placebo group (haz- resorption.
Load more

Recommended publications
  • Abnormal Uterine Bleeding, 108, 113 Acupuncture, 159-160
    Cambridge University Press 978-1-107-45182-7 - Managing the Menopause: 21st Century Solutions Edited by Nick Panay, Paula Briggs and Gab Kovacs Index More information Index abnormal uterine bleeding, 108, American Society of Clinical potential role as reproductive 113 Oncology (ASCO) biomarker, 6 acupuncture, 159–160 guidelines, 143 predicting the menopause, adenomyosis American Society of 14–17 effects of the menopause, 108 Reproductive Medicine, anti-ovarian antibodies, 16 management, 115 198 antral follicle count (AFC), 16 pathophysiology, 109 androgen therapy antral follicles, 2 aging adverse events in women, anxiety and risk of VTE, 185 139–140 cognitive behavior therapy and sexual decline, 104 androgen physiology in (CBT), 88 risk factor for CVD, 36 women, 137 Aristotle, 20 Albright, Fuller, 58 causes of androgen asoprisnil, 125 alendronate, 76–77 insufficiency in women, assisted reproduction, 13–14, alternative therapies 137–138 16 claims made by proponents, considerations when oocyte vitrification, 17–18 158 prescribing for FSD, atherosclerosis, 38 common misunderstandings 140–141 atractylodes in herbal medicine, about, 161 description, 136–137 22 definition, 157 DHEA, 136 atrophic vaginitis direct risks, 159 effectiveness in treating FSD, definition, 52 evidence for effectiveness, 138–139 local estrogen therapies, 48 158–159 for female sexual dysfunction See also vulvo-vaginal expectations of users, (FSD), 137 atrophy. 157–158 indications for, 137 autoimmune disease extent of use for menopausal postmenopausal therapies, and premature
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2001/0047033 A1 Taylor Et Al
    US 20010047033A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2001/0047033 A1 Taylor et al. (43) Pub. Date: Nov. 29, 2001 (54) COMPOSITION FOR AND METHOD OF Publication Classification PREVENTING OR TREATING BREAST CANCER (51) Int. Cl." ........................ A61K 31/35; A61K 31/138 (52) U.S. Cl. ............................................ 514/456; 514/651 (75) Inventors: Richard B. Taylor, Valley Park, MO (US); Edna C. Henley, Athens, GA (57) ABSTRACT (US) The present invention is a composition for preventing, Correspondence Address: minimizing, or reversing the development or growth of Richard B. Taylor breast cancer. The composition contains a combination of a Protein Technologies International, Inc. Selective estrogen receptor modulator Selected from at least P.O. BOX 88940 one of raloxifene, droloxifene, toremifene, 4'-iodotamox St. Louis, MO 63188 (US) ifen, and idoxifene and at least one isoflavone Selected from genistein, daidzein, biochanin A, formononetin, and their (73) Assignee: Protein Technologies International, respective naturally occurring glucosides and glucoside con Inc., St. Louis, MO jugates. The present invention also provides a method of (21) Appl. No.: 09/900,573 preventing, minimizing, or reversing the development or growth of breast cancer in which a Selective estrogen (22) Filed: Jul. 6, 2001 receptor modulator Selected from at least one of raloxifene, droloxifene, toremifene, 4'-iodotamoxifen, and idoxifene is Related U.S. Application Data co-administered with at least one isoflavone Selected from genistein, daidzein, biochanin A, formononetin, and their (62) Division of application No. 09/294,519, filed on Apr. naturally occuring glucosides and glucoside conjugates to a 20, 1999. woman having or predisposed to having breast cancer.
    [Show full text]
  • Blockade of the Stimulatory Effect of Estrogens, OH-Tamoxifen, OH
    ICANCERRESEARCH57,3494-3497.August15.19971 Blockade of the Stimulatory Effect of Estrogens, OH-Tamoxifen, OH-Toremifene, Droloxifene, and Raloxifene on Alkaline Phosphatase Activity by the Antiestrogen EM-800 in Human Endometrial Adenocarcinoma Ishikawa Cells1 Jacques Simard,2 Rocio Sanchez, Donald Poirier, Sylvain Gauthier, Shankar M. Singh, Yves Merand, Alarn Belanger, Claude Labrie, and Fernand Labile Laboratory of Molecular Endocrinology, CHUL Research Center, Quebec, Quebec, GI V 4G2, Canada ABSTRACT Because data suggest that continuous long-term tamoxifen therapy is preferable to its usual short-term use (5), and studies are already in Although temporary benefits of tamoxifen therapy are observed in up progress on the long-term administration of tamoxifen to prevent to 40% of women with breast cancer, this compound, which is known to breast cancer (13), it becomes important to make available a pure possess mixed estrogenic and antiestrogenic activities, has been associated with increased risk of endometrial carcinoma. This study compares the antiestrogen that, due to its lack of estrogenic activity, should theo effects of the novel nonsteroidal pure antiestrogen EM-800 and related retically be more efficient than tamoxifen in treating breast cancer compounds with those of a series of antiestrogens on the estrogen-sensitive while simultaneously eliminating the risk of developing uterine car alkaline phosphatase (AP) activity in human endometrial adenocarcinoma cinoma during its long-term use. This study compares the effect of Ishikawa cells. Exposure to increasing concentrations of up to 1000 nM EM-800 or its active metabolite, EM-652, with those of OH-tamox EM-SOO or its active metabolite EM-652 alone failed to affect basal AP ifen, OH-toremifene, droloxifene, raloxifene, and !CI-182780 (14— activity.
    [Show full text]
  • Design and Synthesis of Selective Estrogen Receptor Β Agonists and Their Hp Armacology K
    Marquette University e-Publications@Marquette Dissertations (2009 -) Dissertations, Theses, and Professional Projects Design and Synthesis of Selective Estrogen Receptor β Agonists and Their hP armacology K. L. Iresha Sampathi Perera Marquette University Recommended Citation Perera, K. L. Iresha Sampathi, "Design and Synthesis of Selective Estrogen Receptor β Agonists and Their hP armacology" (2017). Dissertations (2009 -). 735. https://epublications.marquette.edu/dissertations_mu/735 DESIGN AND SYNTHESIS OF SELECTIVE ESTROGEN RECEPTOR β AGONISTS AND THEIR PHARMACOLOGY by K. L. Iresha Sampathi Perera, B.Sc. (Hons), M.Sc. A Dissertation Submitted to the Faculty of the Graduate School, Marquette University, in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy Milwaukee, Wisconsin August 2017 ABSTRACT DESIGN AND SYNTHESIS OF SELECTIVE ESTROGEN RECEPTOR β AGONISTS AND THEIR PHARMACOLOGY K. L. Iresha Sampathi Perera, B.Sc. (Hons), M.Sc. Marquette University, 2017 Estrogens (17β-estradiol, E2) have garnered considerable attention in influencing cognitive process in relation to phases of the menstrual cycle, aging and menopausal symptoms. However, hormone replacement therapy can have deleterious effects leading to breast and endometrial cancer, predominantly mediated by estrogen receptor-alpha (ERα) the major isoform present in the mammary gland and uterus. Further evidence supports a dominant role of estrogen receptor-beta (ERβ) for improved cognitive effects such as enhanced hippocampal signaling and memory consolidation via estrogen activated signaling cascades. Creation of the ERβ selective ligands is challenging due to high structural similarity of both receptors. Thus far, several ERβ selective agonists have been developed, however, none of these have made it to clinical use due to their lower selectivity or considerable side effects.
    [Show full text]
  • Pure Oestrogen Antagonists for the Treatment of Advanced Breast Cancer
    Endocrine-Related Cancer (2006) 13 689–706 REVIEW Pure oestrogen antagonists for the treatment of advanced breast cancer Anthony Howell CRUK Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Manchester M20 4BX, UK (Requests for offprints should be addressed to A Howell; Email: [email protected]) Abstract For more than 30 years, tamoxifen has been the drug of choice in treating patients with oestrogen receptor (ER)-positive breast tumours. However, research has endeavoured to develop agents that match and improve the clinical efficacy of tamoxifen, but lack its partial agonist effects. The first ‘pure’ oestrogen antagonist was developed in 1987; from this, an even more potent derivative was developed for clinical use, known as fulvestrant (ICI 182,780, ‘Faslodex’). Mechanistic studies have shown that fulvestrant possesses high ER-binding affinity and has multiple effects on ER signalling: it blocks dimerisation and nuclear localisation of the ER, reduces cellular levels of ER and blocks ER-mediated gene transcription. Unlike anti-oestrogens chemically related to tamoxifen, fulvestrant also helps circumvent resistance to tamoxifen. There are extensive data to support the lack of partial agonist effects of fulvestrant and, importantly, its lack of cross-resistance with tamoxifen. In phase III studies in patients with locally advanced or metastatic breast cancer, fulvestrant was at least as effective as anastrozole in patients with tamoxifen-resistant tumours, was effective in the first-line setting and was also well tolerated. These data are supported by experience from the compassionate use of fulvestrant in more heavily pretreated patients. Further studies are now underway to determine the best strategy for sequencing oestrogen endocrine therapies and to optimise dosing regimens offulvestrant.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Identification of Novel Regulatory Genes in Acetaminophen
    IDENTIFICATION OF NOVEL REGULATORY GENES IN ACETAMINOPHEN INDUCED HEPATOCYTE TOXICITY BY A GENOME-WIDE CRISPR/CAS9 SCREEN A THESIS IN Cell Biology and Biophysics and Bioinformatics Presented to the Faculty of the University of Missouri-Kansas City in partial fulfillment of the requirements for the degree DOCTOR OF PHILOSOPHY By KATHERINE ANNE SHORTT B.S, Indiana University, Bloomington, 2011 M.S, University of Missouri, Kansas City, 2014 Kansas City, Missouri 2018 © 2018 Katherine Shortt All Rights Reserved IDENTIFICATION OF NOVEL REGULATORY GENES IN ACETAMINOPHEN INDUCED HEPATOCYTE TOXICITY BY A GENOME-WIDE CRISPR/CAS9 SCREEN Katherine Anne Shortt, Candidate for the Doctor of Philosophy degree, University of Missouri-Kansas City, 2018 ABSTRACT Acetaminophen (APAP) is a commonly used analgesic responsible for over 56,000 overdose-related emergency room visits annually. A long asymptomatic period and limited treatment options result in a high rate of liver failure, generally resulting in either organ transplant or mortality. The underlying molecular mechanisms of injury are not well understood and effective therapy is limited. Identification of previously unknown genetic risk factors would provide new mechanistic insights and new therapeutic targets for APAP induced hepatocyte toxicity or liver injury. This study used a genome-wide CRISPR/Cas9 screen to evaluate genes that are protective against or cause susceptibility to APAP-induced liver injury. HuH7 human hepatocellular carcinoma cells containing CRISPR/Cas9 gene knockouts were treated with 15mM APAP for 30 minutes to 4 days. A gene expression profile was developed based on the 1) top screening hits, 2) overlap with gene expression data of APAP overdosed human patients, and 3) biological interpretation including assessment of known and suspected iii APAP-associated genes and their therapeutic potential, predicted affected biological pathways, and functionally validated candidate genes.
    [Show full text]
  • Diethylstilbestrol and Media Coverage of the "Morning After" Pill
    Diethylstilbestrol and Media Coverage of the "Morning After" Pill DIANE-DINH KIM Luu Communicated by: Dr. Brenda Knowles Hon ors Program ABSTRACT The Food and Drug Administration (FDA) approves numerous prescription medicines everyday. The public consumes them, because they believe that these drugs will be safe and effective. We know that not all drugs are one hundred percent free of risks from other side effects, but we consume them because the FDA has judged them to be safe. There are times when the FDA does not approve the safety of high-demand drugs quickly enough to please the public and the companies that would like to manufacture the medicines. One example of such a situation involves the "morning after" pill. As a result of public demand, the media has pressured the FDA to speed up the approval of Diethylstilbestrol (DES) for use as a "morning after" pill. The misleading, inaccurate, and incomplete information about the "morning after" pill as delivered by journalists has deceived members of the public and has caused them to put even more pressure on the FDA. This pressure may cause the FDA to give less careful consideration to the risks associated with the disease and may ultimately harm many women's health. The popularity of DES in 1970s resulted in tragic outbreaks of cancer in both the users of the drug and their children. By presenting only the benefits of DES, the media jeopardizes the health of many more in the future. INTRODUCTION these concerns and instead presented the drug as a safe and effective contraceptive that the FDA is reluc­ The news media is a powerful force.
    [Show full text]
  • Gungor Serms Manuscript Revised
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by University of Bath Research Portal Citation for published version: Güngör, S, Delgado-Charro, MB, Masini-Etévé, V, Potts, RO & Guy, RH 2013, 'Transdermal flux predictions for selected selective oestrogen receptor modulators (SERMs): Comparison with experimental results', Journal of Controlled Release, vol. 172, no. 3, pp. 601-606. https://doi.org/10.1016/j.jconrel.2013.09.017 DOI: 10.1016/j.jconrel.2013.09.017 Publication date: 2013 Document Version Peer reviewed version Link to publication University of Bath General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Download date: 13. May. 2019 Transdermal Flux Predictions for Selected Selective Estrogen Receptor Modulators (SERMs): Comparison with Experimental Results Sevgi Güngör1,2, M. Begoña Delgado-Charro1, Valérie Masini-Etévé3, Russell O. Potts4, Richard H. Guy1,5 1University of Bath, Department of Pharmacy & Pharmacology, Bath, U.K. 2Department of Pharmaceutical Technology, Faculty of Pharmacy, Istanbul University, Istanbul, Turkey. 3Besins Healthcare SA, Brussels, Belgium. 4Russ Potts Consulting LLC, San Francisco, CA, U.S.A. 5Correspondence: University of Bath, Department of Pharmacy & Pharmacology, Claverton Down Bath, BA2 7AY, U.K. Tel. +44.1225.465433; fax +44.1225.386114; [email protected] Graphical abstract !"#$%&'()*'$+*,-(".(&(/012("+*,( &('&,3*(&,*&(".(4,*&56(57$8( 9*8*6,&:"8( 6;,"<3;( 57$8( &8)( 6,&85#",6( $86"( 5<4%<6&8*"<5(:55<*(( Schematic view of SERM delivery to cancerous breast tissue following application of a topical formualtion over a relatively large area of skin.
    [Show full text]
  • Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
    Molecules 2016, 21, 75; doi:10.3390/molecules21010075 S1 of S110 Supplementary Materials: Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs Fei Mao 1, Wei Ni 1, Xiang Xu 1, Hui Wang 1, Jing Wang 1, Min Ji 1 and Jian Li * Table S1. Common names, indications, CAS Registry Numbers and molecular formulas of 6891 approved drugs. Common Name Indication CAS Number Oral Molecular Formula Abacavir Antiviral 136470-78-5 Y C14H18N6O Abafungin Antifungal 129639-79-8 C21H22N4OS Abamectin Component B1a Anthelminithic 65195-55-3 C48H72O14 Abamectin Component B1b Anthelminithic 65195-56-4 C47H70O14 Abanoquil Adrenergic 90402-40-7 C22H25N3O4 Abaperidone Antipsychotic 183849-43-6 C25H25FN2O5 Abecarnil Anxiolytic 111841-85-1 Y C24H24N2O4 Abiraterone Antineoplastic 154229-19-3 Y C24H31NO Abitesartan Antihypertensive 137882-98-5 C26H31N5O3 Ablukast Bronchodilator 96566-25-5 C28H34O8 Abunidazole Antifungal 91017-58-2 C15H19N3O4 Acadesine Cardiotonic 2627-69-2 Y C9H14N4O5 Acamprosate Alcohol Deterrant 77337-76-9 Y C5H11NO4S Acaprazine Nootropic 55485-20-6 Y C15H21Cl2N3O Acarbose Antidiabetic 56180-94-0 Y C25H43NO18 Acebrochol Steroid 514-50-1 C29H48Br2O2 Acebutolol Antihypertensive 37517-30-9 Y C18H28N2O4 Acecainide Antiarrhythmic 32795-44-1 Y C15H23N3O2 Acecarbromal Sedative 77-66-7 Y C9H15BrN2O3 Aceclidine Cholinergic 827-61-2 C9H15NO2 Aceclofenac Antiinflammatory 89796-99-6 Y C16H13Cl2NO4 Acedapsone Antibiotic 77-46-3 C16H16N2O4S Acediasulfone Sodium Antibiotic 80-03-5 C14H14N2O4S Acedoben Nootropic 556-08-1 C9H9NO3 Acefluranol Steroid
    [Show full text]
  • Effects of Hormone Therapy on Blood Pressure
    Menopause: The Journal of The North American Menopause Society Vol. 22, No. 4, pp. 456/468 DOI: 10.1097/gme.0000000000000322 * 2014 by The North American Menopause Society REVIEW ARTICLE Effects of hormone therapy on blood pressure Zeinab Issa, MD,1 Ellen W. Seely, MD,2 Maya Rahme, MSc,3 and Ghada El-Hajj Fuleihan, MD, MPH3,4 Abstract Objective: Although hormone therapy remains the most efficacious option for the management of vasomotor symptoms of menopause, its effects on blood pressure remain unclear. This review scrutinizes evidence of the mech- anisms of action of hormone therapy on signaling pathways affecting blood pressure and evidence from clinical studies. Methods: Comprehensive Ovid MEDLINE searches were conducted for the terms Bhypertension[ and either of the following Bhormone therapy and menopause[ or Bselective estrogen receptor modulator[ from year 2000 to November 2013. Results: In vitro and physiologic studies did not reveal a clear deleterious effect of hormone therapy on blood pressure. The effect of oral therapy was essentially neutral in large trials conducted in normotensive women with blood pressure as primary outcome. Results from all other trials had several limitations. Oral therapy had a neutral effect on blood pressure in hypertensive women. Transdermal estrogen and micronized progesterone had a beneficial effect on blood pressure in normotensive women and, at most, a neutral effect on hypertensive women. In general, tibolone and raloxifene had a neutral effect on blood pressure in both hypertensive and normotensive women. Conclusions: Large randomized trials are needed to assess the effect of oral hormone therapy on blood pressure as a primary outcome in hypertensive women and the effect of transdermal preparations on both normotensive and hypertensive women.
    [Show full text]